Reprogramming the tumor immune microenvironment via antibody-drug conjugates.
1/5 보강
[INTRODUCTION] Antibody-drug conjugates (ADCs) have revolutionized oncology, yet tumor microenvironment (TME) heterogeneity remains a major barrier.
APA
Xu T, Gu Y, Guan X (2026). Reprogramming the tumor immune microenvironment via antibody-drug conjugates.. Expert opinion on pharmacotherapy, 27(3), 237-252. https://doi.org/10.1080/14656566.2026.2642215
MLA
Xu T, et al.. "Reprogramming the tumor immune microenvironment via antibody-drug conjugates.." Expert opinion on pharmacotherapy, vol. 27, no. 3, 2026, pp. 237-252.
PMID
41796021 ↗
Abstract 한글 요약
[INTRODUCTION] Antibody-drug conjugates (ADCs) have revolutionized oncology, yet tumor microenvironment (TME) heterogeneity remains a major barrier. TME-targeted ADCs offer a paradigm shift by specifically modulating immunosuppressive cellular crosstalk and stromal components to overcome tumor evasion.
[AREAS COVERED] This review summarizes design strategies and clinical progress of TME-targeted ADCs. Literature was searched via PubMed and Embase (2015-2025), focusing on early-phase trials, safety profiles, and translational challenges in advanced solid tumors.
[EXPERT OPINION] The next decade will transition from broad TME disruption to precision engineering. AI-driven spatial omics will refine biomarker-led selection, identifying 'TME phenotypes' for tailored therapy. Emerging multi-immune-axis platforms, such as immunostimulatory antibody conjugates (ISACs) and bispecific ADCs, will transcend single-target limitations. We anticipate regulatory approvals of TME-targeted ADCs for 'cold' tumors within five years, serving as priming agents for immunotherapy. Within ten years, TME-targeted ADCs should migrate to neoadjuvant settings to 'normalize' the tumor ecosystem before surgery. This evolution from treatment in advanced settings to foundational curative therapy, using personalized ADC combinations tailored to individual immune landscapes, will be essential to overcome adaptive resistance and achieve long-term remission.
[AREAS COVERED] This review summarizes design strategies and clinical progress of TME-targeted ADCs. Literature was searched via PubMed and Embase (2015-2025), focusing on early-phase trials, safety profiles, and translational challenges in advanced solid tumors.
[EXPERT OPINION] The next decade will transition from broad TME disruption to precision engineering. AI-driven spatial omics will refine biomarker-led selection, identifying 'TME phenotypes' for tailored therapy. Emerging multi-immune-axis platforms, such as immunostimulatory antibody conjugates (ISACs) and bispecific ADCs, will transcend single-target limitations. We anticipate regulatory approvals of TME-targeted ADCs for 'cold' tumors within five years, serving as priming agents for immunotherapy. Within ten years, TME-targeted ADCs should migrate to neoadjuvant settings to 'normalize' the tumor ecosystem before surgery. This evolution from treatment in advanced settings to foundational curative therapy, using personalized ADC combinations tailored to individual immune landscapes, will be essential to overcome adaptive resistance and achieve long-term remission.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Integrative Single-Cell and Machine Learning Analysis Identifies an EMT-Associated Prognostic Signature for Papillary Thyroid Cancer.
- CD74tumour-Associated Macrophages Promote Immune Escape through Autonomous PD-L1 Eexpression in Gastric Cancer.
- Design, synthesis, and biological evaluation of X19: a matrine pyrazole derivatives therapeutic candidate.
- Status and influencing factors of resilience among patients with lung cancer undergoing chemotherapy: a qualitative study.
- Combined RAS and SMAD4 Mutations and Microsatellite Instability Predict Outcomes in Colorectal Lung Metastases Treated with Image-Guided Thermal Ablation.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.